Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivipansel SC with rHuPH20 in Healthy Subjects
NCT02217917Phase 1Completed
- Sponsor
- GlycoMimetics
- Start
- Oct 2015
- Primary completion
- Apr 2016
- Modality
- Bivalent/Multivalent Binders, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rivipansel in sickle cell disease (SCD) (3 cohorts), sponsored by GlycoMimetics. Primary endpoints: Assessment of adverse events (AEs), Assessment of cardiac conduction intervals as assessed via 12-lead electrocardiogram (ECG) and 2 more. Started Oct 2015; status: completed.
02
Drugs
rivipansel
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02217917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02217917.